Behrouz Keleidari1, Rastin Mohammadi Mofrad2, Shahab Shahabi Shahmiri3, Mohammad Hossein Sanei4, Mohsen Kolahdouzan5, Erfan Sheikhbahaei6. 1. Isfahan Minimally Invasive Surgery and Obesity (IMISO) Center, Department of Surgery, Isfahan University of Medical Sciences, Isfahan, Iran. 2. Department of Surgery, Isfahan University of Medical Sciences, Isfahan, Iran. 3. Isfahan Minimally Invasive Surgery and Obesity (IMISO) Center, Department of Surgery, Isfahan University of Medical Sciences, Isfahan, Iran. shshahabi@yahoo.com. 4. Department of Pathology, Al Zahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. 5. Department of Thoracic Surgery, Al Zahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. 6. Student Research Committee, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract
BACKGROUND: One of the new current treatment options for Diabetes Mellitus is about increasing glucagon-like peptide-1 (GLP-1) activity. GLP-1 with its incretin effect showed major role in glucose homeostasis. Gastroileostomy can increase GLP-1 secretion by rapid delivery of undigested food to the terminal ileum. We studied the early effects of a gastroileostomy on serum levels of GLP-1, glucose, and insulin in rats. METHODS: Gastroileostomies with side-to-side anastomosis were performed on 15 male New Zealand rats. Blood samples were obtained before and 1 week after the gastroileostomy. RESULTS: Our results showed that the rats lost a lot of weight from start (330 ± 15 g) to the end (240 ± 25 g) of the experiment (p = 0.048). The data analysis showed that the gastroileostomy surgery elevates the level of GLP-1in plasma significantly (89.1852 vs. 177.440 respectively; p < 0.001) and caused a significant decrease in plasma glucose as well (92.00 and 66.29 mg/dL respectively; p < 0.001). However, the insulin state elevated after the surgery significantly (8.03 vs. 9.89; p < 0.001). CONCLUSION: In this study, we showed the effectiveness of gastroileostomy treatment to decrease body weight and plasma glucose with increased GLP-1 in rats. This small rat model suggests the potential of this surgery to treat type 2 diabetes mellitus.
BACKGROUND: One of the new current treatment options for Diabetes Mellitus is about increasing glucagon-like peptide-1 (GLP-1) activity. GLP-1 with its incretin effect showed major role in glucose homeostasis. Gastroileostomy can increase GLP-1 secretion by rapid delivery of undigested food to the terminal ileum. We studied the early effects of a gastroileostomy on serum levels of GLP-1, glucose, and insulin in rats. METHODS: Gastroileostomies with side-to-side anastomosis were performed on 15 male New Zealand rats. Blood samples were obtained before and 1 week after the gastroileostomy. RESULTS: Our results showed that the rats lost a lot of weight from start (330 ± 15 g) to the end (240 ± 25 g) of the experiment (p = 0.048). The data analysis showed that the gastroileostomy surgery elevates the level of GLP-1in plasma significantly (89.1852 vs. 177.440 respectively; p < 0.001) and caused a significant decrease in plasma glucose as well (92.00 and 66.29 mg/dL respectively; p < 0.001). However, the insulin state elevated after the surgery significantly (8.03 vs. 9.89; p < 0.001). CONCLUSION: In this study, we showed the effectiveness of gastroileostomy treatment to decrease body weight and plasma glucose with increased GLP-1 in rats. This small rat model suggests the potential of this surgery to treat type 2 diabetes mellitus.
Authors: Rinki Murphy; Nicholas J Evennett; Michael G Clarke; Steven J Robinson; Lee Humphreys; Bronwen Jones; David D Kim; Richard Cutfield; Lindsay D Plank; Hisham Hammodat; Michael W C Booth Journal: BMJ Open Date: 2016-07-04 Impact factor: 2.692
Authors: Bryan Cruz; Rodolfo J Flores; Kevin P Uribe; Evangelina J Espinoza; Charles T Spencer; Katherine M Serafine; Arbi Nazarian; Laura E O'Dell Journal: Neuropsychopharmacology Date: 2019-01-07 Impact factor: 7.853